National Cancer Institute (NCI): Leukemia trials

The registry lists 271 Leukemia studies with National Cancer Institute (NCI) as lead sponsor. 5 are open to participants now and 89 have results posted.

Early Phase 1 1Phase 1 152Phase 2 120Phase 3 8No phase 20(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00058461Phase 2
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00054431Phase 2
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
• Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00049569Not applicable
• Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
• A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)CompletedNCT00045396Phase 2
• Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT00042796Phase 1
• Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerActive, not recruitingNCT00039676
• Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00039117Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
• Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic LeukemiaWithdrawnNCT00030355Phase 1/2
• Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00027872Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic LeukemiaCompletedNCT00025038Phase 2
• BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaWithdrawnNCT00024115Phase 1
• Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous LeukemiaTerminatedNCT00023920Phase 2
• Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaTerminatedNCT00022971Phase 1
• Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic LeukemiaCompletedNCT00022737Phase 3
• Immunotoxin Therapy in Treating Patients With Hairy Cell LeukemiaCompletedNCT00021983Phase 1
• Caspofungin Acetate in Treating Children With Fever and NeutropeniaCompletedNCT00020527Not applicable
• Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or LymphomaCompletedNCT00020111Phase 1
• UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or LeukemiaCompletedNCT00019838Phase 1
• Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00019656Phase 1
• Monoclonal Antibody Therapy in Treating Patients With LeukemiaCompletedNCT00019227Phase 1/2
• Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00019032Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00017472Phase 1
• Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00016302Not applicable
• Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute LeukemiaCompletedNCT00016016Phase 1/2
• STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00015834Phase 1/2
• Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic MalignanciesCompletedNCT00013533Early Phase 1
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
• Thalidomide With or Without Fludarabine in Treating Patients With Hematologic CancerTerminatedNCT00009984Phase 2
• Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00006364Phase 2
• Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
• Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00006226Phase 2
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
• Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedNCT00005942Phase 1/2
• Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous TreatmentCompletedNCT00005811Phase 2
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or LeukemiaTerminatedNCT00005786Not applicable
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
• Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00004918Phase 1/2
• Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00004862Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00003997Phase 1
• Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or LymphomaCompletedNCT00003970Phase 1
• Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic LeukemiaCompletedNCT00003934Phase 3
• 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT00003837Not applicable
• Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT00003694Phase 2
• Flavopiridol in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00003620Phase 2
• 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT00003545Phase 2
• Raltitrexed in Treating Children With Refractory Acute LeukemiaCompletedNCT00003528Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00003190Phase 3
• 506U78 in Treating Patients With Refractory Hematologic CancerCompletedNCT00002970Phase 2
• Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous LeukemiaCompletedNCT00002925Phase 1/2
• Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute LeukemiaCompletedNCT00002912Phase 1
• Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002798Phase 3
• Immunotoxin in Treating Patients With Leukemia or LymphomaCompletedNCT00002765Phase 1
• Topotecan in Treating Children With Refractory LeukemiaCompletedNCT00002705Phase 1
• Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic LeukemiaCompletedNCT00002704Phase 2
• Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002574Phase 2
• Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsCompletedNCT00001830Phase 1
• A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With LeukemiaCompletedNCT00001689Phase 1
• A Phase II Efficacy Study of Roferon-A in Hairy Cell LeukemiaCompletedNCT00001567Phase 2
• Phase I Study of Intrathecal MafosfamideCompletedNCT00001251Phase 1
• Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-TacCompletedNCT00001249Phase 1